TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2439456

Group type: EXPERIMENTAL
Intervention: 3% modified fluid gelatine
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 6% low molecular hydroxyethyl starch
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both plasma substitutes
Number of subjects: 87
Study: 2205704

Group type: EXPERIMENTAL
Intervention: pindolol (15 mg)
Number of subjects: 349

Group type: COMPARATOR
Intervention: atenolol (100 mg)
Number of subjects: 349
Study: 788694

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (1 mg, orally, every 6 hours for two weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no prostaglandin treatment)
Number of subjects: 10
Study: 30972693

Group type: EXPERIMENTAL
Intervention: FIO2 of 14.29% (Group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FIO2 of 12.47% (Group B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FIO2 of 10.82% (Group C)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 28693558

Group type: EXPERIMENTAL
Intervention: 10 mg of elemental zinc orally for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo orally for 14 days
Number of subjects: 0
Study: 25182142

Group type: EXPERIMENTAL
Intervention: 28 g almonds
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 42 g almonds
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (0 g almonds)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Subjective appetite ratings
Number of subjects: 32
Study: 24022423

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (8 oz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Warm water (8 oz)
Number of subjects: 30
Study: 21435092

Group type: EXPERIMENTAL
Intervention: 14-day hybrid therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, amoxicillin, clarithromycin, and metronidazole for 7 days)
Number of subjects: 117
Study: 19394618

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily
Number of subjects: 2860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2860
Study: 16698320

Group type: EXPERIMENTAL
Intervention: Nurses trained in the stages of change model for counselling
Number of subjects: 19
Study: 12939536

Group type: EXPERIMENTAL
Intervention: Walking and jumping training (WJG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Walking training (WG)
Number of subjects: 28
Study: 10824446

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 1%
Number of subjects: 170

Group type: COMPARATOR
Intervention: Terconazole 0.8%
Number of subjects: 170
Study: 8890507

Group type: EXPERIMENTAL
Intervention: Still-face-with-touch (intervention)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Still-face-no-touch (control)
Number of subjects: 48
Study: 1832313

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study: 6606421

Group type: EXPERIMENTAL
Intervention: Single 1.92g dose of co-trimoxazole
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5-day course of co-trimoxazole
Number of subjects: 44
Study: 31063478

Group type: EXPERIMENTAL
Intervention: 150 kcal/session exercise group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 300 kcal/session exercise group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 27892881

Group type: EXPERIMENTAL
Intervention: Visual assessment of coronary stenosis
Number of subjects: 929

Group type: COMPARATOR
Intervention: Quantitative coronary angiography (QCA)
Number of subjects: 929
Study: 26356160

Group type: EXPERIMENTAL
Intervention: Zonisamid
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Zonisamid (after placebo phase)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Zonisamid and Placebo (side effects)
Number of subjects: 207
Study: 23423302

Group type: COMPARATOR
Intervention: L-arginine (ARG) 6 g
Number of subjects: 23

Group type: COMPARATOR
Intervention: L-arginine (ARG) 6 g plus 25 g carbohydrate (ARG + CHO)
Number of subjects: 23
Study: 20872778

Group type: EXPERIMENTAL
Intervention: SB-742457 35 mg/day
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198
Study: 19570158

Group type: EXPERIMENTAL
Intervention: Res-Care intervention
Number of subjects: 487
Study: 16684436

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 203

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 203
Study: 15194366

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for five doses (group I, n = 107)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose every 14 days for two doses (group II, n = 112)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No-antibody induction (group III, n = 78)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: All groups received tacrolimus, mycophenolate mofetil, and steroids for maintenance immunosuppression
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 297
Study: 10673485

Group type: EXPERIMENTAL
Intervention: Printed Index Medicus (n = 32)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Grateful Med (n = 12)
Number of subjects: 103

Group type: COMPARATOR
Intervention: CD-ROM (n = 31)
Number of subjects: 103
Study: 9085314

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE)
Number of subjects: 140
Study: 1489123

Group type: EXPERIMENTAL
Intervention: Capsaicin (10 microM to 50 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine (20 mg and 80 mg from nebulized solutions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citric acid (nebulized solutions 0.125 to 32%)
Number of subjects: 0
Study: 3993874

Group type: EXPERIMENTAL
Intervention: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group II patients upon complaint of worst pain
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group III patients after extubation but before pain complaint
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard volume epidural morphine (2 mg in 10 ml saline) administered to Group I patients upon complaint of worst pain
Number of subjects: 50
Study: 30985540

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (60 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (0.9% saline, 100 ml)
Number of subjects: 60
Study: 30171334

Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 92
Study: 28400374

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with intraocular lens (IOL) implantation plus goniosynechialysis (phaco-GSL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Phacoemulsification with intraocular lens (IOL) implantation only (phaco)
Number of subjects: 26
Study: 25316559

Group type: EXPERIMENTAL
Intervention: Garlic (400 mg garlic and 1 mg allicin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23595874

Group type: EXPERIMENTAL
Intervention: 850 mg pure theobromine (TB)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cocoa intervention (CC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Theobromine and cocoa intervention (TB+CC)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 21694628

Group type: EXPERIMENTAL
Intervention: 10 mg zopiclone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg zopiclone
Number of subjects: 16

Group type: COMPARATOR
Intervention: 50 g ethanol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18269387

Group type: COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine (B5C0)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine with 15 microg clonidine (B5C15)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine with 30 microg clonidine (B5C30)
Number of subjects: 75
Study: 16926554

Group type: EXPERIMENTAL
Intervention: NIHSS score cut point of >=15
Number of subjects: 385
Study: 12616034

Group type: EXPERIMENTAL
Intervention: 0.125 IU/kg rhGH given 3 times a week for the first 4 weeks and 0.25 IU/kg thereafter
Number of subjects: 19
Study: 10710462

Group type: EXPERIMENTAL
Intervention: Gutta‐Condensor
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MecaShaper
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: K‐type ultrasonic file
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lentulo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pastinject
Number of subjects: 50
Study: 9415501

Group type: EXPERIMENTAL
Intervention: Radiofrequency lesioning at 67 degrees C
Number of subjects: 61

Group type: COMPARATOR
Intervention: Radiofrequency lesioning at 40 degrees C (Control)
Number of subjects: 61
Study: 7506471

Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) treatment (0.1 IU.kg‐1 body wt.day‐1 for 7 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) treatment
Number of subjects: 16
Study: 2952826

Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 172

Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 172
Study: 29985440

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug users (including digoxin and sotalol)
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 78615

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 78615

Group type: COMPARATOR
Intervention: Non-users of antiarrhythmic drugs
Number of subjects: 78615
Study: 28264722

Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 1 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 2 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 3 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (needles inserted without manipulation)
Number of subjects: 0
Study: 24579970

Group type: EXPERIMENTAL
Intervention: Fasudil in addition to routine treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 80
Study: 23536997

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 20070415

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg
Number of subjects: 3887
Study: 18847584

Group type: EXPERIMENTAL
Intervention: Second dose of misoprostol 800 mcg vaginally
Number of subjects: 1972
Study: 16373904

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 12611026

Group type: EXPERIMENTAL
Intervention: Functional restoration early intervention (n = 22)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nonintervention group (n = 48)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Low-risk subjects (n = 54)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cost savings associated with early intervention
Number of subjects: 124
Study: 11314870

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unilateral ECT (UL ECT)
Number of subjects: 0
Study: 7636923

Group type: EXPERIMENTAL
Intervention: Maternity waiting home
Number of subjects: 6438

Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 6438
Study: 2677624

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by Nebuhaler
Number of subjects: 27

Group type: COMPARATOR
Intervention: Terbutaline delivered by nebulizer
Number of subjects: 27
Study: 687049

Group type: EXPERIMENTAL
Intervention: Inverted positioning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position (control)
Number of subjects: 20
Study: 31415825

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) administration
Number of subjects: 513

Group type: COMPARATOR
Intervention: sBP decline of at least 5 mmHg
Number of subjects: 513
Study: 30943196

Group type: EXPERIMENTAL
Intervention: ECI visible (change of 12%)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CF visible (range 5‐40g)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (ECI not visible)
Number of subjects: 98
Study: 28103816

Group type: EXPERIMENTAL
Intervention: Self-assessment instrument (Montgomery-Asberg Depression Rating Scale) used in recurrent consultations with GPs, treatment as usual (TAU) for 3 months, with at least 4 visits.
Number of subjects: 258

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) without the self-assessment instrument.
Number of subjects: 258
Study: 25179540

Group type: EXPERIMENTAL
Intervention: Spanish-language HIV/AIDS and HIV testing video
Number of subjects: 150

Group type: COMPARATOR
Intervention: Orally-delivered HIV/AIDS and HIV testing information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Spanish-language HIV/AIDS and HIV testing video (lower health literacy participants)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Orally-delivered HIV/AIDS and HIV testing information (lower health literacy participants)
Number of subjects: 150
Study: 21905158

Group type: EXPERIMENTAL
Intervention: Home-based physical activity counseling (PA group, n = 20) for 3 months via telephone, including weekly PA tip sheets.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Contact control (control group, n = 26).
Number of subjects: 46
Study: 21992075

Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole (L + Let)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Letrozole monotherapy (Let)
Number of subjects: 219
Study: 19090876

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5-25 mg/d
Number of subjects: 33567

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-10 mg/d
Number of subjects: 33567

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-40 mg/d
Number of subjects: 33567
Study: 16542132

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1207
Study: 12681034

Group type: EXPERIMENTAL
Intervention: GyneFix
Number of subjects: 2

Group type: COMPARATOR
Intervention: Gyne-T380S
Number of subjects: 2
Study: 11023764

Group type: EXPERIMENTAL
Intervention: Vaccinated children (first vaccination on the 60th day of life)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Unvaccinated children (first vaccination on the 90th day of life)
Number of subjects: 496
Study: 9032702

Group type: EXPERIMENTAL
Intervention: Glucose solution (0.1 kcal ml‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Milk protein (0.7 kcal ml‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pea peptide hydrolysate (0.2 kcal ml‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Whey peptide hydrolysate (0.2 kcal ml‐1)
Number of subjects: 6
Study: 7690583

Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (5-HTP, 10 micrograms kg-1 min-1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP, 16.6 micrograms kg-1 min-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3538367

Group type: EXPERIMENTAL
Intervention: 5-drug combination therapy (vincristine, carmustine, alkylating agents, and prednisone)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 2-drug combination therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 5-drug combination therapy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Maintenance therapy after remission
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Discontinued therapy after remission
Number of subjects: 67

Group type: COMPARATOR
Intervention: Maintenance therapy vs Discontinued therapy
Number of subjects: 67
Study: 30092324

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg weekly for 16 weeks)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 29887386

Group type: EXPERIMENTAL
Intervention: True Colic Cohort
Number of subjects: 281

Group type: COMPARATOR
Intervention: No Colic Cohort
Number of subjects: 281
Study: 27716697

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) 30 mg/kg in 500 cc normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (500 cc normal saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 80
Study: 24684105

Group type: EXPERIMENTAL
Intervention: EA + GA
Number of subjects: 20

Group type: COMPARATOR
Intervention: GA
Number of subjects: 20
Study: 23230645

Group type: EXPERIMENTAL
Intervention: Fluoride gel (F) alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Fluoride gel (F) combined with chlorhexidine varnishes (CHX)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study: 20424456

Group type: EXPERIMENTAL
Intervention: Diamorphine treatment
Number of subjects: 107

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 107
Study: 18402625

Group type: EXPERIMENTAL
Intervention: New prediction equations for lithium clearance (CL(Li)) for inpatients: CL(Li) = 0.932 + 0.185CL(Cr)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: New prediction equations for lithium clearance (CL(Li)) for outpatients: CL(Li) = 1.021 + 0.141CL(Cr)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily dose (inpatients, mg) = 350.15 + 289.92 (desired lithium level, mmol/L) + 0.84 (weight, kg) - 1.76 (age, years) + 34.43 [TCA, yes = 1, no = 0] + 62.1(CL(Cr), L/h) + 13.1 [BUN, mmol/L] + 40.9 (sex, male = 1, female = 0)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily dose (outpatients, mg) = 784.92 + 530.22 (desired lithium level, mmol/L) + 8.61 (weight, kg) - 12.09 (age, years) - 11.14 (TCA, yes = 1, no = 0) - 7.63 (CL(Cr), L/h) - 42.62 (BUN, mmol/L) - 23.43 (sex, male = 1, female = 0)
Number of subjects: 60
Study: 15808751

Group type: EXPERIMENTAL
Intervention: 0.5 mg of phVEGF-A(165)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plasmid
Number of subjects: 80
Study: 12424582

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Number of subjects: 312

Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines (comparator)
Number of subjects: 312
Study: 10354290

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 38
Study: 8944196

Group type: EXPERIMENTAL
Intervention: Coloured overlays
Number of subjects: 0
Study: 12285561

Group type: EXPERIMENTAL
Intervention: 3 applications of 36 mg quinacrine hydrochloride pellets during the proliferative phase of 3 consecutive menstrual cycles
Number of subjects: 60
Study: 6234966

Group type: EXPERIMENTAL
Intervention: 300 mg rosoxacin by mouth (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 g spectinomycin administered intramuscularly (group A)
Number of subjects: 200
Study: 31434583

Group type: EXPERIMENTAL
Intervention: Monaural pure tones presented at 25 dB
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: LittlEars auditory questionnaire
Number of subjects: 387
Study: 30409152

Group type: EXPERIMENTAL
Intervention: Mesenteric approach (arm B)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Conventional approach (arm A)
Number of subjects: 354
Study: 26856225

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy for obstructive sleep apnea.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral interventions to improve PAP compliance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approaches in the studies (SleepTight and BestAIR).
Number of subjects: 0
Study: 24877116

Group type: EXPERIMENTAL
Intervention: Wii Fit balance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual balance therapy
Number of subjects: 50
Study: 23210416

Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride test dentifrice (SnF2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Amine fluoride/stannous fluoride marketed control dentifrice (AmF/SnF2)
Number of subjects: 27
Study: 20153389

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) mixed with porridge
Number of subjects: 170
Study: 18391643

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise-training program (T)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 90
Study: 16022953

Group type: EXPERIMENTAL
Intervention: Emergency revascularization (ERV)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 87
Study: 12225494

Group type: EXPERIMENTAL
Intervention: Parachute group (intensive psychosocial treatment and support)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Access to a small overnight crisis home
Number of subjects: 253

Group type: COMPARATOR
Intervention: Historical comparison group
Number of subjects: 253

Group type: COMPARATOR
Intervention: Prospective group
Number of subjects: 253
Study: 10348530

Group type: EXPERIMENTAL
Intervention: IVUS-guided stent deployment (group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Angiography + final IVUS assessment (group B)
Number of subjects: 85
Study: 7573630

Group type: EXPERIMENTAL
Intervention: 6-month therapeutic community program
Number of subjects: 628

Group type: COMPARATOR
Intervention: 12-month therapeutic community program
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: 3-month relapse prevention program
Number of subjects: 628

Group type: COMPARATOR
Intervention: 6-month relapse prevention program
Number of subjects: 628
Study: 1767648

Group type: EXPERIMENTAL
Intervention: Autologous blood using the cell saver
Number of subjects: 40

Group type: COMPARATOR
Intervention: Homologous bank blood
Number of subjects: 40
Study: 7355429

Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC) treatment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Anti-platelet therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Natural history of untreated TIA/RIND
Number of subjects: 156
Study: 31515418

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL) treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (spectacles or contact lenses)
Number of subjects: 60